Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.70 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.60 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9776607 | 0.89 | KEAP1 (0.86) | KEAP1HSPA5BCL2BCL2L1ALOX5 | |
| SCHEMBL30616875 | 0.89 | KEAP1 (0.86) | KEAP1HSPA5BCL2BCL2L1ALOX5 | |
| SCHEMBL68653 | 0.83 | KEAP1 (1.00) | KEAP1HSPA5BCL2BCL2L1ALOX5 | |
| SCHEMBL8925742 | 0.83 | KEAP1 (0.76) | KEAP1HSPA5BCL2BCL2L1ALOX5 | |
| SCHEMBL29506902 | 0.83 | KEAP1 (1.00) | KEAP1HSPA5BCL2BCL2L1ALOX5 | |
| SCHEMBL87816 | 0.82 | KEAP1 (0.75) | KEAP1HSPA5BCL2BCL2L1ALOX5 | |
| SCHEMBL30335116 | 0.82 | KEAP1 (0.75) | KEAP1HSPA5BCL2BCL2L1ALOX5 | |
| SCHEMBL920838 | 0.81 | KEAP1 (0.96) | KEAP1HSPA5BCL2BCL2L1ALOX5 | |
| SCHEMBL28998999 | 0.80 | KEAP1 (0.72) | KEAP1HSPA5BCL2BCL2L1ALOX5 | |
| SCHEMBL27940839 | 0.80 | KEAP1 (0.72) | KEAP1HSPA5BCL2BCL2L1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59216896-A | — | — | None | — | — | JP | disclosed |
| EP-1904047-B1 | APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| US-7989656-B2 | Biaryl carboxylic acid apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-08-02 | — | — | US | disclosed |
| CN-101010276-B | Cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing same | CHUGAI PHARMACEUTICAL CO LTD | 2011-01-12 | — | — | CN | disclosed |
| US-20100234456-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| US-7750004-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| US-7371732-B2 | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-7371732-B2 | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-7371732-B2 | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| EP-1904047-A2 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-04-02 | — | — | EP | disclosed |
| CN-101010276-A | Novel cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-08-01 | — | — | CN | disclosed |
| US-20070135392-A1 | Apoptosis promoters | ABBVIE INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007008627-A2 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1699807-A2 | GLUCOPYRANOSYLOXY-SUBSTITUTED AROMATES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF, AND METHODS FOR PRODUCING THE SAME | Boehringer Ingelheim International GmbH (DE) | 2006-09-13 | — | — | EP | disclosed |
| US-20050187168-A1 | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
| WO-2005063785-A2 | GLUCOPYRANOSYLOXY-SUBSTITUTED AROMATES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF, AND METHODS FOR PRODUCING THE SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
| JP-S59216896-A | ORGANIC PHOSPHORIC ESTER AND INSECTICIDE AND ACARICIDE | SANKYO CO LTD | 1984-12-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187168-A1 | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture | SLC5A2, SLC5A1, SLC2A4 | KEAP1 1544/4885HSPA5 1180/4885BCL2 3236/4885 |
| US-20100234456-A1 | APOPTOSIS PROMOTERS | MCL1, BAX, BCL2 | KEAP1 1616/4885HSPA5 678/4885BCL2 3/4885 |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | KEAP1 901/4885HSPA5 2445/4885BCL2 1462/4885 |
| US-20070135392-A1 | Apoptosis promoters | MCL1, BAX, BCL2 | KEAP1 1616/4885HSPA5 678/4885BCL2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.